Estradiol transdermal micro patch - Noven Pharmaceuticals
Alternative Names: Estradot; Minivelle; Vivelle-DotLatest Information Update: 28 Oct 2021
At a glance
- Originator Noven Pharmaceuticals
- Developer Novartis; Noven Pharmaceuticals
- Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
- Mechanism of Action Estrogen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Atrophic vaginitis; Menopausal syndrome; Postmenopausal osteoporosis; Primary ovarian insufficiency; Vasomotor symptoms
Most Recent Events
- 07 Nov 2017 Noven Pharmaceuticals initiates litigation against Alvogen over ANDA submission in USA
- 05 May 2015 Noven Pharmaceuticals and Hisamitsu Pharmaceutical filed first-to-file patent-challenge lawsuit relating to the generic version of Minivelle® in the US against Mylan N.V. and its subsidiaries
- 18 Feb 2015 Launched for Postmenopausal osteoporosis (Prevention) in the US (Transdermal, Minivelle® 0.025 mg/day)